Please use this identifier to cite or link to this item:
Title: Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction
Authors: Pereira, Manuel P.
Zeidler, Claudia
Wallengren, Joanna
Halvorsen, Jon Anders
Weisshaar, Elke
Garcovich, Simone
Misery, Laurent
Brenaut, Emilie
Şavk, Ekin
Potekaev, Nikolay
Lvov, Andrey
Bobko, Svetlana
Szepietowski, Jacek C
Reich, Adam
Bozek, Agnieszka
Legat, Franz J
Metz, Martin
Streit, Markus
Serra-Baldrich, Esther
Gonçalo, Margarida 
Storck, Michael
Nau, Teresa
Hoffmann, Vincent
Steinke, Sabine
Greiwe, Ina
Dugas, Martin
Augustin, Matthias
Ständer, Sonja
Keywords: nodular prurigo; chronic nodular prurigo; patient-reported outcome; itch; pruritus;; therapy
Issue Date: 17-Feb-2021
Publisher: Medical Journals/Acta D-V
Project: European Academy of Dermatology and Venereology (EADV, No. 2016-012 to MP) 
Serial title, monograph or event: Acta Dermato-Venereologica
Volume: 101
Issue: 2
Abstract: Chronic nodular prurigo is characterized by recalcitrant itch. Patient perspectives on therapeutic goals, satisfaction with therapy and efficacy of therapeutic regimens for this condition are unknown. This questionnaire study examined these issues in 406 patients with chronic nodular prurigo from 15 European dermatological centres. Improvements in itch, skin lesions and sleep were the most important goals. Emollients, topical corticosteroids and antihistamines were the most frequently used treatments, while a minority of patients were prescribed potent medications, such as systemic immunosuppressants and gabapentinoids. Most patients were not satisfied with their previous therapy (56.8%), while 9.8% did not receive any therapy despite having active disease. A substantial number of respondents (28.7%) considered none of the therapeutic options effective. Although chronic nodular prurigo is a severe disease, most patients were not treated with potent systemic drugs, which may contribute to the high levels of dissatisfaction and disbelief in available therapies. Specific guidelines for chronic nodular prurigo and the development of novel therapies are necessary to improve care.
ISSN: 1651-2057
DOI: 10.2340/00015555-3726
Rights: openAccess
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais

Show full item record


checked on Sep 1, 2023


checked on Sep 2, 2023

Page view(s)

checked on Sep 25, 2023


checked on Sep 25, 2023

Google ScholarTM




This item is licensed under a Creative Commons License Creative Commons